AKR1B1: Aldo-keto reductase family 1 member B1
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols.
- Drugs that act on it: 4
- Approved: 2
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on AKR1B1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 4
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Arctic Therapeutics125%
- NeuromaxBionevia125%
| Epalrestat | Approved | NeuromaxBionevia | Small molecule | Inhibitor | 3 |
| TolrestatWithdrawn | Approved | — | Small molecule | Inhibitor | 0 |
| Caficrestat | Phase 3 | Arctic Therapeutics | Small molecule | Inhibitor | 2 |
| Sorbinil | Phase 3 | — | Small molecule | Inhibitor | 0 |
| Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | Caficrestat | Phase 2 | Active, not recruiting | Arctic Therapeutics | Jul 21, 2026 |
| Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes | Epalrestat | Phase 2 | Recruiting | Haibo Shao | Apr 30, 2026 |
| Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study | Epalrestat | Not applicable | Active, not recruiting | Zhejiang Chinese Medical University | Mar 26, 2024 |
| Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy. | Epalrestat | Phase 2 / Phase 3 | Recruiting | St. John's Research Institute | Jan 11, 2024 |
| Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Caficrestat | Phase 3 | Active, not recruiting | Applied Therapeutics, Inc. | Sep 10, 2019 |
- Diabetic neuropathy0.43
- Diabetes mellitus0.41
- Neurodegenerative disease0.37
- Diabetic cardiomyopathy0.26
- Hypertensive disorder0.18
- Essential hypertension0.14
- Breast cancer0.12
- Hepatocellular carcinoma0.11
- Gastric cancer0.11
- Neoplasm0.10
- Cancer0.10
- Central nervous system cancer0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1900, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P15121, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets